Opioid REMS: Industry Group Would Add Communication Plan To FDA's Proposal
This article was originally published in The Pink Sheet Daily
Executive Summary
MedGuides for three types of long-acting opioids are more practical than a single document, sponsors tell FDA and advisory committee.
You may also be interested in...
Opioid REMS: Sponsors Share Implementation, But Also Give Up Some Control
Now that FDA has unveiled what it expects in a Risk Evaluation and Mitigation Strategy for long-acting and extended-release opioids, sponsors will be scrambling to write the REMS for their individual products and put together the shared components and implementation system envisioned by the agency.
Opioid REMS: Sponsors Share Implementation, But Also Give Up Some Control
Now that FDA has unveiled what it expects in a Risk Evaluation and Mitigation Strategy for long-acting and extended-release opioids, sponsors will be scrambling to write the REMS for their individual products and put together the shared components and implementation system envisioned by the agency.
The REMS Filibuster: FDA Wants Ability To End Post-Approval Talks, Make Final Decision
FDA wants a bigger stick for product-specific Risk Evaluation and Mitigation Strategy negotiations, if for no other reason than to end the talks and make the final decision.